Jump to: Authorized Access | Attribution | Authorized Requests

Study Description

WHI WHIMS+ GWAS

This substudy contains genotypes generated using Illumina Omni Express on additional WHI European American (EA) participants. When these participants are combined with the GARNET participants, they form a population that is representative of the entire WHI EA HT population. Also, all Women's Health Initiative Memory Study (WHIMS) participants who have the appropriate consent have GWAS data in either this substudy or GARNET. Summary level phenotypes for the WHI Cohort study participants can be viewed at the top-level study page phs000200 WHI Cohort. Individual level phenotype data and molecular data for all WHI top-level study and substudies are available by requesting Authorized Access to the WHI Cohort study phs000200.

Authorized Access
Publicly Available Data
  Link to other NCBI resources related to this study
Study Inclusion/Exclusion Criteria

WHI WHIMS+ GWAS:

The participants selected for this substudy include the following WHI Hormone Trial (HT) EA women who have the appropriate consent for data to be shared on dbGaP: ~4660 WHI Memory Study (WHIMS) participants who were not in GARNET, ~279 women at least 65 years old at enrollment who were neither in WHIMS nor GARNET, and ~899 women younger than age 65 at enrollment who were neither in WHIMS nor GARNET. When these participants are combined with the GARNET participants, they form a population that is representative of the entire WHI EA HT population. Also, all WHIMS participants who have the appropriate consent have GWAS data in either this substudy or GARNET.

WHI

Inclusion criteria: Postmenopausal women, aged 50 to 79, who were able and willing to provide written informed consent and who expected to reside in the study recruitment area for at least 3 years following enrollment were eligible.

Exclusion criteria: Study subjects were excluded from the WHI CT and OS if they had medical conditions predictive of a survival time of less than 3 years; if they were known to have conditions that might affect study participation and adherence (alcoholism, drug dependency, mental illness, dementia); or if they were active participants in another randomized controlled clinical trial. In addition, each CT component incorporated specific exclusionary criteria.

Molecular Data
TypeSourcePlatformNumber of Oligos/SNPsSNP Batch IdComment
Whole Genome Genotyping Illumina HumanOmniExpress 733202 N/A
Study History

  • October 1992 - Clinical Coordinating Center operations begin
  • March 1993 - 16 Clinical Centers selected
  • September 1993 - Recruitment of participants for 2 Hormone Therapy Trials (HT) trials and the Dietary Modification Trial (DM) begins
  • September 1994 - 24 additional Clinical Centers selected; Recruitment of participants for the Observational Study (OS) begins
  • June 1995 - CaD randomization begins
  • August 1998 - Randomization of participants for the DM ends
  • October 1998 - Randomization of participants for the HT ends
  • December 1998 - Recruitment of participants for the OS ends
  • September 2000 - Randomization of participants for the CaD ends
  • July 2002 - Estrogen plus Progestin HT was stopped early and main results published
  • March 2004 - Estrogen-Alone HT was stopped early
  • April 2004 - Main results of Estrogen-Alone HT published; Closeout of OS begins
  • October 2004 - Closeout of clinical trials (HT, DM, and CaD) begins
  • March 2005 - Study close-out ends
  • April 2005 - Extension study begins
  • September 2005 - Final WHI outcomes obtained and WHI database closed
  • February 2006 - Main results of DM and CaD published
  • September 2010 - Extension 1 study closed
  • October 2010 - Extension 2 study begins
  • October 2011 - In Person Visits scheduled to begin
  • December 2012 - In Person Visits scheduled to be complete
  • September 2015 - Extension 2 study scheduled to close

Selected Publications
Diseases/Traits Related to Study (MeSH terms)
Authorized Data Access Requests
Study Attribution
  • Principal Investigator
    • Garnet Anderson, PhD. Fred Hutchinson Cancer Research Center, Seattle, WA USA.
  • Funding Sources
    • HHSN268201100046C. National Heart, Lung, and Blood Institute, National Instiutes of Health, Bethesda, MD, USA.